Tonya Villafana, AstraZeneca global franchise head of infection
AstraZeneca and Sanofi sharpen RSV pitch with new analyses, but how much weight will FDA give them?
As the next-gen RSV vaccine and treatment race continues to heat up, AstraZeneca and Sanofi are putting forth a new dataset they think will help …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
